Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab (Mabscale) vs MabThera in Rheumatoid Arthritis
NCT06175338Phase 1Active, not recruiting
- Sponsor
- Mabscale
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Mabscale. Primary endpoints: Area Under the Curve (Week 2-24), Area Under the Curve (0-inf) and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06175338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175338.